<!--StartFragment-->

**AMR in Cancer Epidemiology : A Growth Concern for Global Health**

Author : Khanh Gia Duong

Introduction : 

Antimicrobial resistance (AMR) is a global health crisis with far-reaching implications across multiple domains, including cancer. The intersection of AMR and cancer poses a significant challenge, as infections caused by resistant pathogens can complicate treatment, increase mortality, and strain healthcare resources.

Method : 

To outline the study design, data sources, and analysis methods to examine the incidence and impact of AMR in cancer patients, researchers can use hospital records, microbiology data, and patient outcomes to analyze the frequency and types of drug-resistant infections that occur in cancer patients. Techniques such as statistical analysis and bioinformatics tools can be used to identify trends and correlations between AMR and cancer-related outcomes.

Results

For instance, it might reveal an increase in the prevalence of multidrug-resistant organisms (MDROs) in oncology wards over recent years. Specific pathogens, such as methicillin-resistant _Staphylococcus aureus_ (MRSA), vancomycin-resistant enterococci (VRE), and extended-spectrum beta-lactamase (ESBL)-producing bacteria, might be identified as major contributors to resistant infections in cancer patients. (Table 1, Amila K. Nanayakkara et al. 2021) The data could show higher mortality rates and longer hospital stays associated with these infections, as well as disruptions in cancer treatment schedules due to complications from resistant infections.

Discussion

The increasing prevalence of AMR in cancer patients is alarming, as it undermines the efficacy of existing cancer therapies. The findings highlight the urgent need for targeted interventions in oncology settings, such as enhanced infection control measures and antibiotic stewardship programs. Overuse of broad-spectrum antibiotics, often necessary in immunocompromised cancer patients, is a significant driver for increasing antibiotic resistance (Amila K. Nanayakkara et al. 2021). The study also underscores the importance of development and mechanisms of antibiotic resistance in bacteria, and future strategies to fight the emerging antimicrobial resistant threat.(Tanvir Mahtab Uddin et al.2021)

Conclusion

AMR in cancer epidemiology presents a growing challenge that significantly impacts patient outcomes and healthcare systems. The increasing prevalence of resistant infections in cancer patients underscores the need for comprehensive strategies to prevent and manage AMR in oncology. By prioritizing research and implementing effective control measures, the medical community can improve the quality of care for cancer patients, ultimately enhancing their chances of successful treatment. The intersection of AMR and cancer underscores the importance of ongoing vigilance and innovation in the face of evolving health threats.

Reference : 

Amila K. Nanayakkara PhD, Helen W. Boucher MD, Vance G. Fowler Jr MD, MHS, Amanda Jezek, Kevin Outterson JD, LLM, David E. Greenberg MD (2021). Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward.CA: A Cancer Journal for Clinicians, 7(6), 488-504 <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21697>

\
Tanvir Mahtab Uddin, Arka Jyoti Chakraborty, Ameer Khusro, BM Redwan Matin Zidan, Saikat Mitra, Talha Bin Emran, Kuldeep Dhama, Md. Kamal Hossain Ripon,Márió Gajdács, Muhammad Umar Khayam Sahibzada, Md. Jamal Hossain, Niranjan Koirala  (2021). Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects.Journal of Infection and Public Health, 14(12), 1750-1766 <https://www.sciencedirect.com/science/article/pii/S1876034121003403>

<!--EndFragment-->
